Which AI agents work with Endo Monitor Lipid Profile Cushing Syndrome Dyslipidemia?

This skill is tagged as working with Claude Code, Claude.ai, OpenAI Codex. SKILL.md is an open format, so most agents that read a skills directory can load it too.

Who published Endo Monitor Lipid Profile Cushing Syndrome Dyslipidemia?

dromlakhani (@dromlakhani) published this skill. Their other Agent Skills are listed on their SkillMD profile.

Endo Monitor Lipid Profile Cushing Syndrome Dyslipidemia by dromlakhani

Name: Endo Monitor Lipid Profile Cushing Syndrome Dyslipidemia
Rating: 4.2 (5 reviews)
Author: dromlakhani

Endo Monitor Lipid Profile Cushing Syndrome Dyslipidemia

Recommends monitoring the lipid profile at diagnosis and periodically thereafter to identify dyslipidemia in adult patients with Cushing syndrome. Triggered by phrases such as "Patient diagnosed with Cushing syndrome", "Assessing for lipid abnormalities in endocrine disorder", or "Screening for dyslipidemia in cortisol excess".

dromlakhani Updated Sep 8, 2026 10 repo stars

File contents

Monitor lipid profile to identify dyslipidemia in Cushing syndrome

STEP 1 — Gather Information

Obtain a lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides) at the time of Cushing syndrome diagnosis and periodically thereafter as determined by the treating physician. Use fasting or nonfasting samples; repeat fasting if triglycerides are elevated or genetic dyslipidemia suspected.

STEP 2 — Rule In / Rule Out

Rule in dyslipidemia if any lipid parameter exceeds normal ranges: LDL-C >70 mg/dL, triglycerides >150 mg/dL, HDL-C <40 mg/dL in men or <50 mg/dL in women. Rule out dyslipidemia if all parameters are within normal limits.

STEP 3 — Classify or Stratify

If dyslipidemia is present, assess atherosclerotic cardiovascular disease (ASCVD) risk using the Pooled Cohort Equations and consider risk-enhancing factors (e.g., visceral obesity, hypertension, diabetes, elevated lipoprotein[a]).

STEP 4 — Decide

If dyslipidemia is identified, advise lifestyle modification and consider statin therapy as adjunct to reduce cardiovascular risk, per guideline 7.2; if lipids remain normal, continue routine monitoring at physician discretion.

Clinical Guardrails / Mimics / Pitfalls

Do not rely solely on total cholesterol; evaluate all lipid components. Avoid initiating statin therapy without confirming LDL-C >70 mg/dL, especially when patients are on ketoconazole (which increases statin levels and myopathy risk). Do not assume lipid-lowering therapy is appropriate for patients with limited life expectancy (e.g., underlying malignancy). Remember that triglycerides >500 mg/dL contraindicate bile acid sequestrants.

Concrete Clinical Example

A 45-year-old woman with newly diagnosed adrenal adenoma–causing Cushing syndrome presents for initial evaluation. Lipid panel shows LDL-C 130 mg/dL, triglycerides 200 mg/dL, HDL-C 35 mg/dL. Dyslipidemia is ruled in; she is advised on diet and exercise, and statin therapy is considered after discussing risks/benefits.

Source: Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2020, doi:10.1210/clinem/dgaa674

---name: endo-monitor-lipid-profile-cushing-syndrome-dyslipidemiadescription: Recommends monitoring the lipid profile at diagnosis and periodically thereafter to identify dyslipidemia in adult patients with Cushing syndrome. Triggered by phrases such as "Patient diagnosed with Cushing syndrome", "Assessing for lipid abnormalities in endocrine disorder", or "Screening for dyslipidemia in cortisol excess".---# Monitor lipid profile to identify dyslipidemia in Cushing syndrome## STEP 1 — Gather InformationObtain a lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides) at the time of Cushing syndrome diagnosis and periodically thereafter as determined by the treating physician. Use fasting or nonfasting samples; repeat fasting if triglycerides are elevated or genetic dyslipidemia suspected.## STEP 2 — Rule In / Rule OutRule in dyslipidemia if any lipid parameter exceeds normal ranges: LDL-C >70 mg/dL, triglycerides >150 mg/dL, HDL-C <40 mg/dL in men or <50 mg/dL in women. Rule out dyslipidemia if all parameters are within normal limits.## STEP 3 — Classify or StratifyIf dyslipidemia is present, assess atherosclerotic cardiovascular disease (ASCVD) risk using the Pooled Cohort Equations and consider risk-enhancing factors (e.g., visceral obesity, hypertension, diabetes, elevated lipoprotein[a]).## STEP 4 — DecideIf dyslipidemia is identified, advise lifestyle modification and consider statin therapy as adjunct to reduce cardiovascular risk, per guideline 7.2; if lipids remain normal, continue routine monitoring at physician discretion.## Clinical Guardrails / Mimics / PitfallsDo not rely solely on total cholesterol; evaluate all lipid components. Avoid initiating statin therapy without confirming LDL-C >70 mg/dL, especially when patients are on ketoconazole (which increases statin levels and myopathy risk). Do not assume lipid-lowering therapy is appropriate for patients with limited life expectancy (e.g., underlying malignancy). Remember that triglycerides >500 mg/dL contraindicate bile acid sequestrants.## Concrete Clinical ExampleA 45-year-old woman with newly diagnosed adrenal adenoma–causing Cushing syndrome presents for initial evaluation. Lipid panel shows LDL-C 130 mg/dL, triglycerides 200 mg/dL, HDL-C 35 mg/dL. Dyslipidemia is ruled in; she is advised on diet and exercise, and statin therapy is considered after discussing risks/benefits.**Source:** Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2020, doi:10.1210/clinem/dgaa674

Frequently asked questions